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Muscle wasting is an important component of the process of
cachexia. In a study of lung cancer patients who had lost 30% of
their pre-illness stable weight, there was a 13% decrease in lean
body mass, when compared to a group of controls matched for
age, sex, height and pre-illness stable weight (Preston et al, 1987).
This overall change reflected a 75% decrease in skeletal muscle
protein, but with no change in visceral protein mass. This deple-
tion of skeletal muscle mass would lead to significant impairment
of respiratory function (Windsor and Hill, 1988), followed by
death of the patient from hypostatic pneumonia. Thus in order to
devise effective therapy for this condition it is necessary to under-
stand the mechanism by which selective depletion of skeletal
muscle occurs. 
A number of studies have provided evidence for an increased
whole-body protein turnover in patients with lung (Heber et al,
1982), colon (Fearon et al, 1988) and hepatocellular carcinoma
(O’Keefe et al, 1990). This may be due to a depression in protein
synthesis (Eden et al, 1984), an increase in protein degradation
(Lundholm et al, 1976) or a combination of the 2. A depression in
muscle protein synthesis was observed in weight-losing cancer
patients without a change in total body protein synthesis or degra-
dation (Eden et al, 1984). In these patients muscle protein
synthesis only accounted for 8% of total body protein synthesis
compared with 53% for healthy controls. Thus the maintenance of
the total protein synthetic rate in these patients appears to be due to
a 2-fold increase in non-skeletal muscle protein synthesis, most
likely arising from an increased hepatic production of acute phase
proteins (Fearon et al, 1991). 
We have recently isolated a proteolysis-inducing factor (PIF),
both from a cachexia-inducing murine tumour (Todorov et al,
1996a), and from the urine and tumours of patients with cancer
cachexia and a range of tumour types (Cariuk et al, 1997).
Administration of PIF to normal mice produced a 10% loss of
overall body weight in 24 h, with selective depletion of lean body
mass (Todorov et al, 1996a; Cariuk et al, 1997). Soleus and
gastrocnemius muscle weights decreased, while kidney and heart
remained unchanged (Lorite et al, 1998). The mechanism by
which PIF induces protein degradation in skeletal muscle is not
known, but previous studies have shown this to be an energy-
dependent process, with no contribution from either the lysosomal
or calcium dependent proteolytic pathways (Lorite et al, 1998). In
cachectic mice bearing the MAC16 tumour, there is an enhanced
expression of the components of the ATP-ubiquitin-dependent
proteolytic pathway (Lorite et al, 1998). Since PIF has been shown
to be responsible for the cachexia in this model, this study reports
changes in the expression of key components of this pathway in
mice administered PIF. To confirm that PIF exerts a direct effect
on the pathway parallel studies have been carried out in C2C12
murine myoblasts in vitro. This surrogate model system was
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myoblasts to undergo an increased protein degradation in the
presence of PIF. 
MATERIALS AND METHODS 
Animals 
Pure strain female NMRI mice (18–20 g) were obtained from our
own breeding colony and were fed a rat and mouse diet (Special
Diet Services, Witham, Essex, United Kingdom) and water ad
libitum. Fragments of the MAC16 tumour, excised from donor
animals with established weight loss, were implanted into the
flanks of NMRI mice (20–25 g) by means of a trocar as described
(Beck and Tisdale, 1987). Tumours were excised from mice with
weight loss between 20 and 25% and used to purify PIF, as agreed
by the Coordinating Committee on Cancer Research of the United
Kingdom for the welfare of animals with neoplasms. 
Purification of PIF 
PIF was purified from solid MAC16 tumours by homogenization
and precipitation of the protein with ammonium sulfate (40%
w/v). The supernatant formed by centrifugation at 4000 g was
subjected to affinity chromatography using a monoclonal antibody
immobilized to a protein A matrix as described (Todorov et al,
1996b). The immunogenic fractions were concentrated and used
without further purification, since the major contaminant was PIF
bound to albumin. 
Isolation of RNA and Northern blot analysis 
Solid MAC16 tumours were excised from donor NMRI mice with
weight loss between 20 and 25% and were used to purify PIF using
affinity chromatography as described (Todorov et al, 1996b).
Female NMRI mice (20 g) were injected into the tail vein with
either PIF (7–10 mg in 100 ml PBS) or PBS as a control, 4 times at
2.5 h intervals starting at 10.00 h (Todorov et al, 1996a; Cariuk et
al, 1997). After 24 h from the first injection the animals were
terminated and total RNA was extracted from gastrocnemius
muscle and heart using the acid guanidinium isothiocyanate/
phenol/chloroform-isoamylalcohol method (Chomczynski and
Sacchi, 1987) and quantitated by absorbance at 260/280 nm. Total
RNA (10 mg) was heat-denatured at 65°C for 10 min and elec-
trophoresed in 1.2% (w/v) agarose gels containing 0.67% form-
aldehyde. The RNA was electrophoretically transferred onto a
nylon membrane (Gene Screen, NEN Research Products, 
MA, USA) and covalently linked to the membrane using a
Spectrolinker XL-1000 UV cross-linker (120 000 mJ cm–2).
Membranes were prehybridized at 42°C in formamide (50%),
dextran sulfate (10%), NaCl (1 M), bovine serum albumin (0.2%),
polyvinylpyrolidone (0.2%), Ficol (0.2%), sodium pyrophosphate
(0.1%), sodium dodecyl sulfate (1%), Tris.HCl (0.05 M, pH 7.5)
and denatured salmon sperm DNA (100 mg ml–1). The cDNA
probes used were for ubiquitin (Wing and Goldberg, 1993),
purchased from the American Type Culture Collection, the 14 K
E2 ubiquitin carrier protein (Wing and Banville, 1994), a 0.6-kb
KspI/KpnI fragment of the coding region, kindly provided by Dr
Simon Wing (McGill University, Montreal, Canada), rat protea-
some subunit 9 (Kumatori et al, 1990) kindly donated by Dr
Walter Spevak (Boehringer Ingelheim, Vienna, Austria) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal
standard. The cDNA probes were labelled to high specific 
activity (~109 cpm mg DNA–1) using the Amersham Megaprime
DNA labelling system (Amersham, Bucks, United Kingdom).
Hybridization was performed at 42°C, overnight, after which the
membranes were washed twice with 30 mM trisodium citrate and
300 mM sodium chloride (2 ´ SSC buffer), followed by incuba-
tion twice for 1 h with SSC-1% SDS, with a final wash with 0.1 ´
SSC for 5 min at room temperature. Quantitation was either by
instantimager recording (Packard, Berks, UK) or by densitometric
scanning of autoradiographs. Relative amounts of RNA loaded in
each lane were visualized by staining with ethidium bromide. 
Measurement of total protein breakdown 
C2C12 myoblasts were seeded at 4 ´ 104 cells per well in 2 ml
Dubecco’s modified Eagles medium in 6-well multidishes. After
24 h cells were labelled with L-[2,6-3H] phenylalanine (10 ml per
ml of medium of a stock solution containing 75 mmoles L-pheny-
lalanine and 50 mCi L-[2,6-3H] phenylalanine per ml) for 24 h.
After labelling the cells were washed in PBS, pre-incubated in
fresh DMEM for 2 h without phenol red (3 ml) in the presence
of antibody (10 mg ml–1) or proteasome inhibitors prior to the
addition of PIF and phenylalanine (2 mM). The amount of
radioactivity released into the medium during a 24 h period was
measured as described (Smith et al, 1999). 
Measurement of proteasome activity 
The activity of 26S proteasomes was measured according to the
method of Orino et al (1991), with some modifications. C2C12
myoblasts were washed twice in ice-cold PBS and sonicated in
20 mM Tris. HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2 and 1 mM
dithiothreitol by 3 pulses of 15 s with a 10s interval. The sonicate
was then centrifuged for 10 min at 15 000 rpm at 4°C and the
resulting supernatant used for assay. About 1 ml of the cell lysate
(about 5 mg protein) was loaded onto 14 ml of a linear gradient of
10–40% (v/v) glycerol in sonicating buffer. The gradient was
centrifuged at 24 000 rpm for 22 h at 4°C and 0.5 ml fractions
were collected for the determination of chymotrypsin-like-activity
of the proteasome. Activity was determined using the fluorogenic
substrate succinyl-LLVY-MCA (0.1 mM) in 100 mM Tris. HCl,
pH 8.0 and 10 ml of each fraction. The reaction was terminated by
the addition of 80 mM sodium acetate and the fluorescence was
measured with an excitation of 360 nm and an emission of
460 nm. The protein concentration of the sample was determined
using the Bradford assay (Sigma Chemical Co, Poole, Dorset,
UK). This method was also used for gastrocnemius and heart
muscle extracts. 
Western blot analysis 
Samples (5 mg protein) were resolved on 10% sodium dodecylsul-
fate, polyacrylamide gels and transferred to 0.45 mm nitrocellulose
membranes (Hybond A, Amersham, UK), which had been blocked
with 5% Marvel in Tris buffered saline (TBS) at 4°C overnight.
The primary antibodies used were rabbit polyclonal antisera to the
20S proteasome core (Affiniti Research Products, Exeter, UK) at a
dilution of 1:1000 and mouse anti-human MSSI (equivalent to the
S7 regulatory subunit of the 26S proteasome (Dubiel et al, 1993) at
a 1:1000 dilution. The secondary antibodies were peroxidase-
conjugated, either goat anti-rabbit, (Sigma Chemical Co, Dorset,
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1:2000 dilution. Incubation was carried out for 2 h at room temper-
ature and development was by enhanced chemiluminescence
(ECL) (Amersham, UK). 
Statistical analysis 
Differences between single groups were analysed by Student’s 
t-test, while multiple group comparisons were made by ANOVA
followed by Tuckey’s test. 
RESULTS 
Intravenous administration of PIF to female NMRI mice produced
a progressive decrease in body weight as previously reported
(Todorov et al, 1996a, 1996b; Cariuk et al, 1997). In the experi-
ment depicted in Figures 1 and 2 the animals had lost 1.55 ± 0.12 g
(8.2% of starting weight P < 0.001 from control) within 24 h of the
first injection of PIF. This weight loss represented loss of lean
body mass with a 17% decrease in wet weight of soleus muscles
and a 16% decrease in protein content. Previous studies have
shown a significant elevation of the high molecular mass conju-
gates of ubiquitin in the soluble gastrocnemius muscle proteins
after treatment with PIF (Lorite et al, 1998). The expression of
both transcripts of ubiquitin (+ 70% for the 1.2 kb mRNA species
and + 64% for the 2.4 kb species P < 0.05 from control) were also
increased in gastrocnemius muscle 24 h after administration of PIF
(Figure 1A). This suggests that the ATP-ubiquitin-dependent
proteolytic pathway was activated by PIF. However, since ubiq-
uitin has roles other than in proteolysis (St John et al, 1986) the
mRNA for other components of the pathway was investigated. The
RNA blots were therefore probed with the cDNA of the Mr 14 000
E2, one of the few E2 species functioning in E3-dependent ubiq-
uitin-conjugate formation (Wing and Banville, 1994). 2 mRNA
transcripts of 1.2 and 1.8 kb were detectable with this probe arising
from different sites of polyadenylation (Figure 1B). There was an
increase in the mRNA levels for both transcripts in the gastrocne-
mius muscle of mice administered PIF, compared with control
animals, with a more pronounced increase in the 1.2 kb transcript
(+ 83% P < 0.05 from control) than the 1.8 kb transcript (+31%).
This effect was specific to skeletal muscle, since heart from PIF-
treated animals showed only a marginal increase in the 1.2 kb E2
transcript, and no change in the 1.8 kb transcript compared with
control animals (Figure 1C). Hybridization of the RNA blots with
cDNA encoding the C9 subunit of the 20S proteasome, the prote-
olytic core of the 26S proteasome, which degrades ubiquitin
conjugates, showed almost a doubling of the 1.3 kb transcript in
PIF-treated mice compared with PBS-treated controls (from 1931
± 813 to 3866 ± 721 arbitary units in PIF-treated mice). Control
experiments showed that the level of mRNA for GAPDH, a house-
keeping gene unrelated to protein breakdown, and RNA loading
was similar in both groups of mice, as evidenced by ethidium
bromide staining of gels. 
These coordinate changes in gene expression suggest that
enhanced ATP-ubiquitin-dependent proteolysis was responsible
for muscle protein catabolism induced by PIF. To determine
whether PIF also produced increased intracellular protein levels of
the proteasome complex cellular extracts from gastrocnemius
muscle were Western blotted using a rabbit polyclonal antibody to
the 20S proteasome core. 2 major bands were observed with mole-
cular masses between 25 and 30 000 Daltons corresponding with
subunits of the proteasomal catalytic complex (Figure 2A). When
compared with control animals densitometric analysis showed a 7-
fold increase in both the lower molecular weight subunit (P <
0.005) and the higher molecular weight subumit (P < 0.02) in PIF-
treated animals. Western analysis of gastrocnemius muscle of PIF-
treated mice using anti-MSSI showed a 2-fold (P < 0.01) increase
in the expression of a protein of Mr ~ 50 000, equivalent to the S7
subunit of the proteasome (Dubiel et al, 1993) (Figure 2B), while
there was no change in the expression of this protein in the hearts
of PIF-treated animals (Figure 2C). There was a 2.8-fold increase
in the functional activity of the proteasome, as determined by the
chymotrypsin-like activity, in gastrocnemius muscle from PIF-
treated mice, using the fluorogenic substrate succinylLLVY-MCA,
while there was no significant change in heart muscle (Figure 2D).
These results confirm that PIF upregulates the proteasome prote-
olytic pathway only in skeletal muscle. 
To determine whether PIF acted directly to invoke these
changes in gene expression further studies were conducted
employing C2C12 murine myoblasts, since PIF has been previously
shown to enhance protein degradation in these cells as a result of
increased production of 15-HETE (Smith et al, 1999). The release
of [3H] phenylalanine from prelabelled cells was used as an index
of proteolysis. PIF produced a dose-related elevation of protein
breakdown with a maximal effect at 2–4 nM (Figure 3), which was
attenuated by a monoclonal antibody to PIF (Todorov et al, 1996b)
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Figure 1 Expression of mRNA for ubiquitin and 14KE2 in gastrocnemius
muscle. (A) Ubiquitin, (B) 14KE2 ubiquitin carrier protein in gastrocnemius
muscle and (C) heart from mice administered either PBS (lanes 1–3) or PIF
(lanes 4–6) 24 h after the first injection. Kb (kilobase), size of the transcripts (Figure 3A), and the reversible proteasome inhibitor benzyloxy-
carbonyl-Leu-Leu-L-norvalinal (MG115) (Lee and Goldberg,
1996) at concentrations between 1 and 50 mM (Figure 3B). The
effect was completely inhibited by the highly specific and irre-
versible proteasome inhibitor lactacystin, which does not inhibit
lysosomal protein degradation in the cell (Fenteany and Schreiber,
1998), at a concentration of 10 mM. Glycerol gradient analysis of
soluble extracts of C2C12 cells showed chymotrypsin-like enzyme
activity in fractions 5–12, which was elevated in PIF-treated cells
(Figure 4A). Western blot analysis of these fractions using 
anti-MSSI antibody, confirmed the presence of a protein of
Mr ~ 50 000 (24) (Figure 4B). Western blot analysis of C2C12 cells
treated with PIF showed an increased expression of MSSI at
concentrations as low as 1.0 nM (Figure 4C), with further
increases up to 4 nM, after which there was a decrease in expres-
sion with further concentrations of PIF. Thus the dose–response
curve for induction of proteasome expression by PIF correlated
with that for protein degradation (Figure 4), confirming that PIF
acts to directly stimulate the proteasome pathway in C2C12 cells in
vitro. 
DISCUSSION 
There are 3 major proteolytic pathways involved in the intracel-
lular degradation of proteins, the lysosomal pathway, Ca2+-
activated proteinases and the ubiquitin-proteasome system.
Lysosomal proteolysis plays a minor role in skeletal muscle
protein breakdown (Attaix and Taillander, 1998), while the Ca2+-
dependent proteinases may be qualitatively important for the
degradation of specific, but quantitatively minor proteins. In
contrast the ATP-ubiquitin-dependent pathway plays an important
role in muscle protein degradation induced by starvation (Wing
and Goldberg, 1993), sepsis (Voisin et al, 1996), metabolic
acidosis (Mitch et al, 1994), denervation atrophy (Medina et al,
1995), head trauma (Mansoor et al, 1996) and cancer cachexia,
both in animal models (Temparis et al, 1994; Lorite et al, 1998),
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Figure 2 Expression of proteasome subunits in gastrocnemius muscle. (A) Western blot analysis of soluble extracts of gastrocnemius muscles of mice 24 h
after administration of PBS (lanes 1–3) or PIF (lanes 4–6) fractionated on 10% SDS-polyacrylamide gels and detected with rabbit polyclonal antibody to the 20S
proteasome core (Affiniti Research Products, Exeter, UK) at a dilution of 1:1000. (B) As above but detected with mouse anti-human MSSI antibody at a dilution
of 1:1000. (C) Western blot analysis of soluble extracts of heart muscle after administration of either PBS (lanes 1–4) or PIF (lanes 5–9) detected with mouse
anti-human MSS1 antibody. Development was by an ECL system (Amersham, UK) using either peroxidase conjugated goat anti-rabbit Ig, (A) or sheep anti-
mouse Ig, (B) and (C) (D) chymotryptic activity of soluble extracts of gastrocnemius muscle and heart from PIF-treated (hatched boxes) and control (open
boxes) mice. The results are expressed as mean ± SEM where n = 5. Differences from control are expressed as a, P = 0.008 as determined by Student’s t-test 
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Figure 3 Effect of murine anti-PIF monoclonal antibody and the
proteasome inhibitor MG115 on PIF-induced protein catabolism. (A) C2C12
myoblasts were incubated with PIF alone (x) or with anti-PIF Ig (10 mgml–1)
(n) and protein degradation was determined after 24 h as in methods.
(B) C2C12 myoblasts were incubated with PIF alone (x) or in the presence of
MG115 at 1 (l), 10 (l l) and 50 (l) mM and protein degradation was
determined after 24 h. Results are shown as mean ± SEM, where n = 9.
Differences from control cultures incubated in the absence of PIF are
indicated as a, P = 0.05 and b, P < 0.01, while differences from PIF-treated
cells are indicated as c, P < 0.05, d, P < 0.01 and e, P < 0.005 using 2-way
ANOVA followed by Tuckey’s test and cancer patients (Attaix and Taillander, 1998). In this process
ubiquitin is first activated by a ubiquitin-activating enzyme (E1),
which then transfers the ubiquitin to a carrier protein (E2), which
either ligates the ubiquitin directly to the target protein, or does so
in the presence of a ubiquitin-protein ligase (E3). Conjugation
mediated by E2 has been suggested to be a rate-limiting step in the
pathway (Wing and Banville, 1994). 
Previous in vivo studies with PIF have shown an energy require-
ment for proteolysis and an increase in ubiquitin-protein conju-
gates in gastrocnemius muscle (Lorite et al, 1998). The present
study has provided evidence for an enhanced expression of
components of the ATP-ubiquitin-dependent proteolytic pathway
within 24 h of administration of PIF. Thus Northern blots showed
mRNA levels for ubiquitin, the Mr 14 000 ubiquitin-conjugating
enzyme (E2), as well as the proteasome subunit C9, to be all
significantly increased in gastrocnemius muscle. Such changes
occur rapidly, and in animals with normal food intake, despite the
loss of body weight, and in a coordinate manner, as they do in
experimental models of cancer cachexia (Temparis et al, 1994;
Lorite et al, 1998). The Mr 14 000 E2 species best supports E3-
dependent conjugate formation and protein breakdown (Wing and
Banville, 1994). 2 mRNA transcripts of 1.2 and 1.8 kb were
detectable arising from different sites of polyadenylation. Of the 2,
the 1.2 kb transcript showed the major elevation after PIF adminis-
tration. The 1.2 kb transcript has also been reported to be increased
in starvation (Wing and Banville, 1994), sepsis (Voisin et al,
1996), dexamethasone treatment (Dardevet et al, 1995) and exper-
imental cancer cachexia (Temparis et al, 1994; Lorite et al, 1998),
while the 1.8 kb transcript is not significantly changed. The rele-
vance of this elevation of the 1.2 kb transcript to protein degrada-
tion induced by PIF is shown by the lack of an enhanced
expression in both heart and liver (not shown) for which wasting is
not observed (Lorite et al, 1998). An enhanced proteasome activity
was also observed, together with increased expression of the 20S
proteasome core and the 19S regulatory subunit. Increased gene
expression of proteasomal subunits has been suggested (Temparis
et al, 1994) to be rate-limiting for protein breakdown. 
These changes in expression of the components of the ATP-
ubiquitin-dependent proteolytic pathway arise from a direct effect of
PIF and are not due to the induction of intermediary facilitators in the
host. Thus C2C12 myoblasts in vitro responded to PIF by an increase
in protein degradation, which was dose-related and inhibited by
higher concentrations of PIF (Smith et al, 1999). This was associated
with an increase in the chymotryptic activity of the 26S proteasome,
and an increase in an ATPase, MSSI, equivalent to the S7 subunit of
the proteasome (Dubiel et al, 1993). In addition the proteasome
inhibitors MG115 and lactacystin completely attenuated protein
degradation induced by PIF, confirming the relevance of activation of
the proteasome pathway to catabolism of muscle proteins. 
Few other agents are known to activate this pathway directly.
Enhanced skeletal muscle proteolysis in rats after tumour necrosis
factor-a (TNF-a) administration is associated with an increased
gene expression and higher levels of free and conjugated ubiquitin
(Garcia-Martinez et al, 1993). This has been attributed to a direct
effect of TNF-a since incubation of isolated rat soleus muscle with
TNF-a for 180 min caused an increase in ubiquitin gene expres-
sion, although there was no change in the expression of the C8
proteasome subunit (Llovera et al, 1997). However, care must be
taken in interpreting these results to mean an activation of the
ATP-ubiquitin-dependent proteolytic pathway, because ubiquitin
has roles other than in proteolysis (St John et al, 1986). Using
C2C12 myotubes as a model of muscle Ebisui et al (1995) showed
TNF-a to have no effect on the mRNA level of subunits C2 and
C8 of the 20S proteasome and subunit S4 of the 26S proteasome,
while interleukin-6 (IL-6) caused an increased expression of all
subunits and reduced the half-life of long-lived proteins. 
The signals mediating the response of PIF to the coordinate
upregulation of ubiquitin, E2 and proteasome subunits are
unknown, but could involve metabolites of arachidonic acid. We
have shown (Smith et al, 1999) that PIF produced an increased
release of arachidonic acid from C2C12 myoblasts that was blocked
by eicosapentaenoic acid, an inhibitor of protein degradation. The
arachidonic acid was metabolized to prostaglandins and hydroxye-
icosatetraenoic acids (HETE), but only 15-HETE produced a
significant increase in protein degradation. Further studies will
attempt to elucidate the mechanisms involved. 
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Figure 4 (A) Separation and expression of proteasomes. Glycerol gradient
analysis of proteasomes from C2C12 cells either untreated (x), or treated with
PIF at 2 (l l) or 4 (l) nM for 24 h. Proteolytic activity was separated from the
main protein peak. The data have been normalized to take account of
variations in protein content of the individual fractions. (B) Western blot
analysis of fractions from the glycerol gradient in A (2.4 mg protein)
fractionated on 10% SDS-polyacrylamide gels and detected with anti-human
MSSI at a 1:1000 dilution. Detection was by an ECL system (Amersham, UK)
using peroxidase conjugated sheep anti-mouse 1 g. (C) Western analysis of
unfractionated supernatants of C2C12 myoblasts, performed as in (B) 24 h
after addition of either PBS (lane 1) or 10 (lane 2), 4.0 (lane 3), 2.0 (lane 4),
1.0 (lane 5) or 0.5 (lane 6) nM PIF. The densitometric values are (arbitrary
units), lane 1, 12; lane 2, 82; lane 3, 106; lane 4, 113; lane 5, 130 and lane 6,
41 
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